[May 11, 2017] |
|
Personalized Medicine (PM) Connective Announces Achievement of Several Milestones
The Personalized Medicine (PM) Connective announced the achievement of
several milestones today. Jeff Waldron, Executive Director of the PM
Connective, highlighted the developments, which include creating a
new leadership panel, securing a second round of funding, and increasing
brand awareness.
At the PM Connective's Strategic Task Force Meeting in March, Waldron
announced the formation of an Advisory Panel for the PM Connective to be
comprised of senior ambassadors to help open doors and represent the
organization externally. Peter Keeling, CEO of Diaceutics and
Chairman of the PM Connective's Board said, "We are pleased to announce
that Peter Kapitein has agreed to serve as Chairman of our new
Advisory Panel. Peter is the inspirational founder and leader of
Inspire2Live, a Netherlands-based patient advocacy organization working
to inspire patients, clinicians, and researchers to work together to get
cancer under control by 2021 and to help people lead healthy lives in
harmony with cancer. He will be recruiting 3-4 additional visionaries to
join him on the Advisory Panel.
Kapitein described his passion that "personalized medicine has the
capacity to transform healthcare, but we must always maintain the
patient-centric focus . . . because our true success will be measured in
health outcomes and the quality of life for patients and their families."
Concurrent with the formation of the Advisory Panel, Waldron also
announced that the PM Connective just received funding from Cardinal
Health. Cardinal Health, a global, integrated healthcare services and
products company, provides customized solutions for hospital systems,
pharmacies, ambulatory surgery centers, clinical laboratories and
physician offices worldwide, and ranks among the top 25 on the Fortune
500. They join Diaceutics as the inaugural funders of the PM Connective.
Tiffany Olson (News - Alert), President of Nuclear Pharmacy Services (NPS) at
ardinal Health and a PM Connective Task Force member, sponsored the
funding. She explained, "Personalized Medicine has been talked about for
decades, but it is unlikely to deliver on its original promise without
rethinking how to deliver radical change. Therefore, the PM Connective's
disease-specific approach, combined with bringing together the silos of
healthcare, will model that radical change, clinically and economically."
Following on the heels of these two milestones, the just released
March/April issue of the Journal of Precision Medicine features a
pair of articles on the PM Connective . . . one introducing the
background and mission and the second summarizing results from the
initial workshops. Waldron emphasized, "These two articles in the
Journal of PM highlight the progress the PM Connective has made through
our first two melanoma workshops hosted by the Rutgers Cancer Institute.
These daylong sessions featured collaborators from the major healthcare
silos that collectively generated 19 key issues and melanoma
interventions to be quantified in our proprietary valuation framework.
We will define the benefits in both health outcomes and economic terms
not only across all of the silos in aggregate . . . but also for each
individual silo to ensure that our model for personalized medicine
doesn't disadvantage any stakeholder."
This culminates a partnership with the Journal of PM that began last
August when Waldron co-led a Roundtable on Overcoming
Obstacles to Personalized Medicine at the Journal's Precision
Medicine Leaders' Summit in San Diego along with Katie Johansen Taber,
VP of PM for the AMA. The PM Connective will be participating in this
Summit again on August 21-24 in San Diego.
Finally, in mid-February, the PM Connective attended the Melanoma
Research Alliance Scientific Retreat in Washington . . . a premier
melanoma gathering of key leaders from major academic, research,
clinical, industry, and patient advocacy groups. At the pre-Retreat
session for patient advocates and foundations, Jeff introduced
the PM Connective and its unique mission. He explained "We are seeking
to become integrators in personalized medicine starting with
melanoma, which is highly curable if diagnosed and treated early. Our
preliminary data shows prompt diagnosis and first-line treatment has the
power to transform patient outcomes and dramatically lower healthcare
costs as a result."
___________________________________________________
About the Personalized (PM) Medicine Connective
The PM Connective is a 501(c)(6) not-for-profit organization registered
in New Jersey. Two hundred healthcare experts representing most major
stakeholder groups conceived it in 2015. They convened in Dublin and set
aside their competitive agendas to search for an answer to the question
"how can we advance personalized medicine?" The consensus felt that
disconnected stakeholders . . . each in their own silo . . . was
restraining PM from achieving its potential. Thus, the PM Connective was
launched as an unbiased facilitator to drive collaboration and
integration across all healthcare industry silos. The founders felt it
should be focused at the disease-specific level in order to produce a
more implementable solution. After significant research, it was decided
to begin with metastatic melanoma and to design a PM model with a
corresponding valuation framework to prove the clinical and economic
benefits of personalized healthcare.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170511005021/en/
[ Back To Homepage ]
|